Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bangkok project tests Same-Day hepatitis c care in community centers

NCT ID NCT05479760

Disease control Sponsor: Institute of HIV Research and Innovation Foundation, Thailand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a same-day approach to hepatitis C testing and treatment in community organizations in Bangkok, Thailand. It involved 200 adults who tested positive for hepatitis C antibodies. The goal was to see if offering immediate treatment with direct-acting antivirals (DAAs) at the community site, along with telehealth follow-ups, could improve the number of people who start and finish treatment compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Direct-acting antivirals (DAAs) for hepatitis C
What this could lead to
If successful, this approach could make hepatitis C testing and treatment faster and more accessible for high-risk communities, potentially reducing transmission.
What could go wrong
This is a small demonstration project (200 people) in one city, so results may not apply elsewhere. Reinfection remains possible after cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Aug 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility criteria for assessment of effectiveness outcomes: Inclusion Criteria: * Thai citizen * 18 years or older * Signed informed consent * Tested anti-HCV positive Exclusion Criteria: * Decline to participate in the research Eligibility criteria assessment of implementation outcomes: Inclusion criteria: * Client level: Tested anti-HCV positive at one of the implementing CBOs * Provider level: KP lay providers providing KP-led Same Day HCV Test and Treat * Leadership level: leadership of implementing CBOs * Government level: involved in policy making related to HCV testing and treatment in key populations Exclusion criteria: * Do not provide informed consent to participate in the research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCV, HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCV, HIV

Contacts and locations

Locations

  • Institute of HIV Research and Innovation

    Pathum Wan, Bangkok, 10330, Thailand

  • MPLUS Foundation (MPLUS)

    Chiang Mai, 50100, Thailand

  • Rainbow Sky Association of Thailand (RSAT)

    Bangkok, Bangkapi, 10240, Thailand

  • The Service Workers In Group Foundation (SWING)

    Bangkok, Building 3, Patpong, Surawong Road, 10500, Thailand